Evidence notes
Evidence, with its edges visible.
The studies behind the questions—and the conclusions they cannot support.
These are selected reading notes, not a systematic review or a complete treatment guideline. Each note separates the published finding from my interpretation of its relevance. Research links were checked in November 2026; these notes have not been reviewed by a clinician.
01 / ATOMIC
Randomized phase 3 · colon cancerAdding immunotherapy after surgery
In resected stage III dMMR colon cancer, ATOMIC compared mFOLFOX6 with or without atezolizumab. The published three-year disease-free survival estimates were 86.3% versus 76.2%, a 10.1 percentage-point difference. The hazard ratio for recurrence or death was 0.50. Grade 3–4 adverse events were reported in 84.1% versus 71.9%. [1]
What it supports: benefit from adding atezolizumab to the studied chemotherapy regimen in the studied population.
What it does not test: appendix cancer specifically, atezolizumab alone, substituting CAPOX for mFOLFOX6, or a shorter chemotherapy course.
My question: how should a specialist apply this evidence to resected dMMR appendiceal cancer?
02 / Dostarlimab before planned surgery
Phase 2 · dMMR solid tumorsResponse in an intact tumor is a different setting
This study treated dMMR tumors with dostarlimab before planned surgery. In the mixed nonrectal cohort, 35 of 54 people who completed treatment had a clinical complete response. That group included different tumor sites; it is not a colon-only or appendix-specific result. [2]
What it supports: substantial activity and the possibility of organ preservation for selected patients in this study.
What it does not establish: that immunotherapy alone after appendix surgery gives the same protection as another postoperative strategy. A clinical complete response is not proof of lifelong cure.
My question: which postoperative evidence or trial can address the actual decision?
03 / ctDNA in appendiceal adenocarcinoma
Observational · blood mutation profilingA negative blood result needs context
A study of blood-based mutation profiling found that appendiceal adenocarcinomas were less likely to have detectable ctDNA than colorectal cancers. Detection also varied with disease features. [3]
What it suggests: blood testing can have important detection limits in appendix cancer.
What it does not establish: the accuracy of every tumor-informed residual-disease test after surgery, or that a negative result safely permits omission of treatment.
My question: what would this exact assay’s result change in my case?
My rule for using a number
Keep the population, treatment, outcome, and follow-up period beside it. Do not turn a trial average into a personal prediction. If an estimate depends on several extrapolations, those assumptions belong next to the estimate, not in a footnote.
Sources & scope
- Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer ↗ATOMIC investigators · New England Journal of Medicine. Randomized postoperative colon-cancer trial. Not an appendix-cancer or immunotherapy-alone trial.
- Nonoperative Management of Mismatch Repair–Deficient Tumors ↗Cercek and colleagues · New England Journal of Medicine. Phase 2 study of immunotherapy before planned surgery, with separate rectal and mixed nonrectal cohorts.
- The Landscape of ctDNA in Appendiceal Adenocarcinoma ↗Clinical Cancer Research · institutional publication record. Blood-based mutation profiling. Its detection rates are not the sensitivity of every tumor-informed residual-disease assay.
Research links checked November 2026. Patient-written interpretation; not a clinical review.